AstraZeneca ends R&D in India


Pharmaceutical firm AstraZeneca (AZ) is quitting its R&D site in Bangalore, India. The closure means 168 employees, researching neglected tropical diseases, tuberculosis (TB) and malaria, will lose their jobs as AZ drops its early-stage research into these areas.

The company will retain more advanced projects, such as AZD5847, which is in Phase II trials against TB. It will also outsource the site’s current product development functions, or transfer them to Macclesfield, UK. However, AZ confirmed it will maintain access to its compound library for open innovation projects in neglected diseases.

The closure is part of AZs ongoing restructuring programme, which began last year, will cost a total of 1600 jobs worldwide and see the company’s main UK R&D activities move from Alderley Park to Cambridge. After the closure, AZ will have just over 1000 staff in India, across manufacturing, sales and marketing roles.


Related Content

Global AstraZeneca restructuring will cost 1600 jobs

19 March 2013 Business

news image

Firm will focus drug development efforts in three strategic R&D centres in the UK, Sweden and the US

Generation next

29 January 2014 Educated Chemist

news image

AstraZeneca is investing in the future of drug discovery with its new graduate training scheme in pharma. Manisha Lalloo find...

Most Read

Magnetic resonance taken to the limit

21 November 2014 Research

news image

Technique can read the spin of a single nucleus opening up a new way to investigate proteins and complex molecules

Boron and beryllium finally shake hands

24 November 2014 Research

news image

Never-before-seen bond observed between periodic table neighbours

Most Commented

A year of water splitting from one device

21 November 2014 Research

news image

Coating protects electrodes from corrosion to keep photoelectrochemical cell running

Nanostripe controversy in new twist

24 November 2014 Research

news image

Creator of striped nanoparticles insists questions over structures have already been answered and accuses critics of a 'perso...